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Abstract 
Background: Data on the use of blood products in sub-Saharan Africa (SSA) are scarce. A 
systematic review of published data on blood utilization according to diagnosis in SSA was 
performed. 
Study design and methods: Studies published from January 2000 to June 2018 were 
searched in PubMed, Embase and African Index Medicus. Data were extracted and 
synthesized. The proportion of blood products used for different diagnostic categories is 
presented.  
Results: 37 studies representing 159,746 transfusions to 96,690 patients from 14 countries in 
SSA were included. Data from six of 37 studies were pooled to determine blood product use 
according to diagnosis. The primary diagnostic categories were pediatric malaria (20%), 
sickle cell anemia [SCA] (18%), obstetric hemorrhage (16%), and other causes of bleeding 
(16%). About 8%, 6% and 2% of products were used for other infections, cancer treatment, 
and surgery respectively. Overall, 58.5% of the products transfused were red blood cells, 31.7 
% whole blood, 7.2% fresh frozen plasma, and 2.6% as platelets. Estimated blood product use 
per population in SSA was 5.3 transfusions per 1000 people, compared with 52 and 34 per 
thousand for Australia and United States respectively. 
Conclusion: This study provides a systematic attempt to quantify blood utilization for SSA. 
Blood products in SSA are used primarily for pediatric malaria, SCA, obstetric hemorrhage 
and other causes of bleeding. Studies such as this represent an important early step towards 
improving hemovigilance in SSA.  
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Introduction 
Blood and blood products are used in clinical care to treat disease conditions that cannot be 
effectively managed by other means, thus averting their morbidity and mortality risk 
potential.1 In most low and middle income countries, blood products are in short supply, 
presenting enormous challenges related to their effective utilization. National blood 
transfusion services (NBTS) were established in most African nations in the early part of this 
century in line with the World Health Assembly resolution WHA28.72 on utilization and 
supply of human blood and blood products. While these services have improved the situation, 
shortages remain. Documenting blood utilization in sub-Saharan Africa (SSA) is an important 
step in understanding the current level of population-based utilization and to forecast future 
demand for blood.2 Both of these factors are fundamental to hemovigilance and to 
improvement of transfusion practice and healthcare systems in SSA. 
In SSA, published data on the clinical use of blood and blood products are limited, although 
estimates for the common indications for transfusion have been made. It has been estimated 
that about 80% of all blood transfusions in SSA are given to three disease conditions, namely; 
malaria, obstetric hemorrhage, and trauma.3 However, some reports have highlighted the 
possibility that recent improvements in the prevention of malaria and the promising progress 
towards its elimination in some parts of the region may have had an impact on blood 
utilization.4-6  Moreover a few recent studies have suggested that in some settings blood 
utilization has shifted to the support of patients suffering from cancer and other non-
communicable diseases.7,8 More comprehensive evidence is therefore needed.   
 
 
 
 
 
 
Materials and methods 
Where applicable, the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) 
guidelines9 were followed in designing and reporting this review. We reviewed the published 
literature on the use of blood and blood products for transfusion in SSA (which includes 49 
countries). An experienced medical Librarian (RS) searched PubMed, Embase (through Ovid) 
and African Index Medicus for articles from January 1, 2000 up to 18 June 2018. The search 
terms used were "Transfusion", "Blood Transfusion", "Blood Component Transfusion", 
"Exchange Transfusion, Whole Blood", and "Plasma Exchange". Our search included studies 
published in English or French. We restricted the date of publication to after January 1, 2000, 
because most African nations established national blood transfusion services (NBTS) around 
the year 2000.10  
The search strategies are reported in Appendix 1. These searches were loaded into EndNote 
software version X7 (Clarivate Analytics, Philadelphia, PA, USA) and duplicates for 
overlapping references were removed. In addition, systematic snow balling was used to search 
other resources by looking at the reference lists of included articles using ‘Scopus citation 
database’. 
Selection of studies: We included cross-sectional studies reporting the use of blood products 
in SSA. Studies reporting on transfusion with any one or more of the following products were 
selected: red blood cells (RBCs), whole blood (WB), platelets (PLTs), and plasma or fresh 
frozen plasma (FFP). Case reports and case series were excluded.  Studies were selected using 
a pre-determined eligibility criteria stipulated in the protocol in Appendix 2. One review 
author (AD) screened all titles and abstracts of articles identified. Only clearly ineligible 
studies were excluded at this stage. Subsequently, full texts of all the remaining 110 studies (3 
in French and 107 in English) were retrieved and read for detailed evaluation.  
 
 
Data extraction: Two review authors (AD and EKB) independently extracted data for each 
study using a piloted data extraction form. We extracted data on the general aspects about the 
study such as the first author, country, study setting, and study duration, as well as the 
outcome variable – the use of blood products. Blood product use was defined as an individual 
transfusion episode for each blood product. The primary outcome was the proportion of blood 
products used for different diagnostic categories, and was calculated as; the number of 
transfusions for a given diagnostic category divided by the total number of blood products 
transfused. Where the data were not clear in an individual study, attempts were made to 
clarify via email to the respective authors. Health facilities were grouped by level, based on a 
three-tier healthcare delivery system. We defined tertiary health facility level as: national 
referral, regional referral or provincial, and university teaching and specialist hospitals; while 
secondary included district level or general hospitals and state hospitals, and primary as health 
centers and health posts. Transfusion index was computed as: number of blood products 
transfused divided by the total number of patients transfused. 
Statistical analysis: The abstracted data were entered into an Excel spreadsheet (Excel 2010, 
Microsoft Corp., Redmond, WA), and exported into SPSS Statistics 23.0 (IBM Corp., 
Armonk, NY) for analysis. The primary outcome graph was made using Prism 7 software 
(GraphPad, La Jolla, CA). Continuous data were summarized with medians and interquartile 
ranges (IQR), while categorical data were summarized with frequencies and percentages. Sub-
group analysis was done for different patient populations, as per the included studies.  
 
 
 
 
 
 
 
Results 
We screened 2143 abstracts, and reviewed 110 full-text articles, from which only 37 studies 
were included. The other 74 studies were excluded for reasons as outlined in Fig. 1.  
The 37 studies included were conducted in 14 of the 49 countries across the SSA region, 
representing 159,746 blood products transfused to 96,690 patients (Appendix 3.1).  
10 of these studies reported data on general patient populations, while the rest were among 
specific patients groups. By geographical location, these were fairly well distributed, although 
the size of the studies included varied widely, as shown in Fig. 2. 
 
Quantitative analysis 
Approximately 75% of the included studies came from tertiary level healthcare facilities in 
urban settings. More than half were retrospective, with a median (IQR) sample size of 144 
(100 – 670) patients. Median study duration (IQR) was 12 (5 – 34) months, and the median 
number of transfusions was 238 (141 – 887) (Table 1). 
Primary outcome measure 
Data from ten studies that reported on general patient populations7, 8, 11- 18 were considered for 
analysis of the primary outcome, but only six studies7,13-16, 18 could be used for this analysis 
because two did not report specific diagnostic categories12,17 and the other two did so using 
ICD-10 disease categories8, 11 (Appendix 3.2). We found that among the general patient 
population, the majority of blood products were used for the following diagnostic categories: 
pediatric malaria (20%), sickle cell anemia (18%), obstetric hemorrhage (16%), and other 
causes of bleeding (16%), as shown in Fig. 3 and Appendix 3.2. The six studies7,13-16, 18 used 
to determine the primary outcome were conducted in only five of the 49 countries across SSA, 
in which 37,195 products were transfused to 33,229 patients (Appendices 3.1 and 3.2). Seven 
 
 
of the 10 general studies7,12-16, 18 also reported on blood utilization by the different wards, 
including pediatrics which used the majority (47%) of blood products (Table 2).  
Sub-groups analysis 
Blood utilization among the other patient populations of pediatrics, obstetrics and gynecology, 
Cesarean section births, and newborns are shown in Appendices 3.3 – 3.7.  The studies among 
pediatric patients23-31 showed that 64% (2810/4387) of blood products were  transfused for 
malaria. Post-partum hemorrage (PPH) at 24% (524/2228) and cesarean sections at 22% 
(485/2228) were the most transfused diagnostic categories among the obstetrics and 
gynecology patients,32-36 with abortions and cancer accounting for only 10% and 8% of 
transfusions respectively. Within the cesarean section only studies,37-39 placenta previa at 27% 
(47/431) and obstructed labor at 25% (44/431) were the leading indications for transfusion. 
Among newborn babies, whole blood and packed RBCs products were used in relatively 
equal measure, and neonatal jaundice and bleeding together accounted for 66% (218/477) of 
the products transfused overall.40-42  
Blood products 
Among the 10 studies on general patient populations,7, 8, 11- 18 transfusions of whole blood 
(WB), red blood cells (RBCs), fresh frozen plasma (FFP), and platelets (PLTs) were 31.7 % 
(46,653/147,310), 58.5% (86,236/147,310), 7.2% (10,662/147,310) and 2.6% 
(3,759/147,310), respectively (Table 3). 
The use of FFP and PLTs was less frequent across the other sub-group studies. Similarly, 
some products were notably reported by very few studies. For example, cryoprecipitate use 
was reported in only one study.11 The two studies that exclusively evaluated the use of 
autologous whole blood and another two on PLTs are summarized in Appendix 3.8.  The 
transfusion index, defined as the number of products per transfused-patient, computed using 
all 37 studies was 1.65 (159,746 products per 96,690 transfused-patients).     
 
 
 
Estimating the number of transfusions per population  
The number of transfusions per population may represent a novel measure of the utilization of 
blood products suitable for comparison across different healthcare regions.  We attempted to 
estimated this for SSA using Tanzania, for which Drammeh et al has documented the national 
annual blood use.12 An estimate of 244,535 red cell units were issued in 2013 in Tanzania for 
an estimated Tanzania national population of 46,142,004 million people in 2013, based on the 
2012 population and housing census.19 We can estimate the number of transfusions in 2013 in 
Tanzania as; 244,535/46,142,004 = 5.3 transfusions per 1000 people. By comparison in the 
same year, Australia issued 1,185,732 blood products with a population of 22,730,000 people, 
giving an estimate of 52.1 transfusions per 1000 people;20 and the United States (AABB 
member facilities) transfused a total of 10,962,000 products (RBCs, WB, PLT, FFP and 
Cryoprecipitates) with a population of 319,330,000, representing 34.3 transfusions per 1000 
people.21, 22  
 
Qualitative synthesis 
All the 37 eligible studies reported utilization of blood and blood products, but with slight 
variations in the scope and quality. Regarding the scope, eight studies reported use of blood 
products among hospitalized general patient populations,7, 11,13-18 while two studies used 
national blood transfusion databases.8,12 These 10 studies were used for the primary outcome 
calculation. The rest of the studies evaluated blood utilizations among specific patient groups: 
nine studies among pediatric patients only;23-31 five on obstetrics and gynecology patients;32-36 
three among cesarean section deliveries;37-39 three among newborn babies;40-42 two among 
elective surgical operations;43,44 two exclusively on the use of platelets;45,46 two on the use of 
autologous blood;47,48 and one among hepato-gastroenterology patients.49 Most studies made a 
 
 
clear distinction between the number of patients transfused and the number of blood products 
used for transfusion. The majority reported both, while eight studies reported on one of the 
two. We contacted the eight authors in order to get clarification, but received no response 
from them. We therefore assumed the number of patients transfused and that of products 
transfused to be equal. Similarly, studies did not specify the number of platelet units used in 
standard platelet transfusions.  Thus, in the case of platelets, the number of blood products is 
more likely to represent the number of transfusion episodes. 
 
Studies varied considerably in the way they reported the disease conditions for which 
transfusions were given. The majority reported discrete diagnostic categories; however, two 
studies8,11 used the International Classification of Diseases (ICD-10) diagnostic categories, 
with many patients grouped into “Other ICD-10 diseases” and “Diseases of blood and blood 
forming organs”. We performed a sensitivity analysis with the assumption that the category 
“Other ICD-10 diseases” falls into our category “Other non-communicable diseases and organ 
disorders”, while “Diseases of blood and blood forming organs” falls into “Other medical 
conditions such as chronic or unknown anemia”. The results showed remarkable differences 
in the outcome measure, especially given the large numbers of blood units in the two ICD-10 
categories from the study performed by Pitman et al.8 We therefore decided not to include 
these two studies in the primary outcome analysis, since it would be misleading to combine 
data with heterogeneous diagnostic categories.  
 
Regarding quality of the studies, one concern was the inconsistency by some studies in 
reporting values, particularly varying denominators in different results tables as well as 
mixing up the indications for transfusion.32-34 In such cases, we resorted to reporting broad 
diagnostic categories or re-calculated the proportions for the blood products, using the rates of 
 
 
transfusion for the individual study. In two instances where the totals from the manuscript 
tables could not be reconciled with those in the text,11,13 the totals from the tables were used.  
 
Because the majority (20/37) of included studies were retrospective chart reviews of paper-
based records, the risk concern for information bias resulting from missing data from the 
archives cannot be overlooked. Few studies made a mention of missing records, and only 
one,8 explained in detail how this matter was handled. We regarded the risk of information 
bias as high for one study in the pediatric population that excluded transfusions done at the 
emergency ward.31 Because of the same challenge of missing data, two large studies that used 
NBTS database,8,12 used the assumption that all blood products distributed by NBTS were 
transfused to the same patients, as requested. In this case, we considered the actual number of 
blood products issued, rather than those requested. In addition, because the proportions of 
products used for the different indications were not reported, we assumed that the proportions 
of requested and issued products would remain the same. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
This review analyzes 37 studies that reported on the use of blood products in SSA, from 
which six studies, reporting on a general hospitalized patient population, 7, 13-16, 18 were used to 
estimate current blood utilization in the region. The results suggest that pediatric malaria, 
sickle cell anemia (SCA), obstetric hemorrhage, and other causes of bleeding are the most 
common indications for which blood is transfused in SSA. We found parallel patterns both for 
the individual hospital wards, with most products being given to the pediatric ward, as well as 
for sub-group patient populations. In the pooled analysis of the nine studies that included only 
children23-31 it was found that 64% of blood products were used for children with severe 
malaria. Similarly, from the five pooled studies in obstetrics and gynecology32-36 over half 
(54%) of blood products were used for obstetric hemorrhage (represented here by the 
diagnostic categories of post-partum hemorrhage [PPH], antepartum hemorrhage [APH], and 
cesarean deliveries). The current review has shown that ‘other cause of bleeding’ is the fourth 
leading transfusion indication, using up to 16% of blood products. This category constituted 
non-traumatic bleedings, with the largest single diagnosis being gastrointestinal bleeding. 
 
Our review confirms evidence from earlier reports that have shown pediatric malaria, obstetric 
hemorrhage, and SCA to be the leading disease conditions for blood transfusion in SSA.3,50,51 
Although our review includes publications as early as the year 2000, the burden of each of 
these diseases still remains high in SSA. Globally malarial anemia is the third most common 
cause of anemia,52 while the prevalence of the sickle cell gene in some parts of SSA ranges 
between 10% and 18%,53,54 with up to 3% of hospitalized children suffering from SCA.55 
Similarly, the prevalence of PPH (the most common type of obstetric hemorrhage) in SSA 
ranges between 10% and 23% of deliveries.56  
 
 
 
Two recent reports (Butler et al and Pitman et al) have indicated that changes are taking place 
in the use of blood in some SSA settings, with blood being used more for cancer and non-
communicable diseases.7,8 Nevertheless, our review has found that pediatric malaria, SCA and 
obstetric hemorrhage still remain the top indications for blood utilization, similar to earlier 
reports. The differences in findings between the present systematic review and the two recent 
studies could relate to the broader assessment of this systematic review and to specific aspects 
of the patient populations included in the two studies. For example, the study by Butler et al 
was conducted at a national referral health facility that handles mainly specialized patient 
care, including cancer care.7 The findings from Pitman et al may be confounded by possible 
mis-categorization of malaria transfusions, a study limitation the authors acknowledge in their 
paper.8  
 
Whereas blood utilization in most developed countries have been documented to be generally 
decreasing,57 the picture in SSA still remains uncertain due to limited data. Some reports have 
suggested that the decrease in blood transfusions in some settings follows a decline in the 
malaria edemicity.4-6 These observations still need to be confirmed by larger prospective 
studies. Blood utilization tends to vary considerably by health care specialty and by level of 
health facility.58 The current review was unable to study these possible trends, because there 
were too few studies to compare urban versus rural setting, tertiary versus secondary level 
health facilities, or studies conducted in early 2000 versus recent years. 
 
We estimated a transfusion index, defined as number of products per transfused patient, and 
found a much lower transfusion index for SSA compared with the United States (1.65 and 
2.72 respectively).21 Similarly, the use of the different blood products varied between SSA 
and high income countries such as the United States with 58.5%, 31.7%, 7.2%  and  2.6%, 
 
 
versus 66%, 0.1%, 19% and 14%  for RBCs, WB, FFP and PLTs, respectively.21 Possible 
explanations for these findings, especially the high percentage of WB use in SSA, could be 
factors associated with limited clinical awareness, the high cost of component separation, as 
well as the local blood demand for WB. Whereas the latter aligns with the WHO 
recommendation for blood products use,1 in general policies and practices related to 
component use in SSA remain unclear. 59 However, lower FFP and PLT use in SSA may be 
related to the high cost investment required to prepare and store these components. 
 
Compared with high income countries, the blood product use per population in SSA is very 
low. We have estimated the annual transfusions per population (using Tanzanian data) to be 
5.3 transfusions per 1000 people, compared to 52.1 and 34.3 per 1000 people for Australia 
and United States respectively. These figures parallel the WHO estimates of 32.0 red cell 
units (range of 7-49) per 1000 population and 3.41 red cell units (range of 0.32-10) per 1000 
population in high-income and low-income countries respectively. 60 The low transfusion rates 
in low-income nations are linked to lower donation rates, which in turn are to a great extent a 
result of inadequate funding.  WHO data estimate donation rates of only 4.6 donations per 
1000 population per year for low-income countries.61 However, to align with the World 
Health Assembly resolution WHA63.12 on availability, safety and quality of blood products, 
SSA nations need to improve blood availability to meet the increasing demand for 
transfusion.62   
 
Limitations: Interpretations of the findings of this current review may be subject to a few 
uncertainties. First, most studies included were retrospective chart reviews conducted with 
non-representative sample of patients and associated with missing data. This increases the risk 
of bias in the individual studies. Moreover, data have not been published for all nations of 
 
 
SSA: only six studies from 10% (five out of 49) of SSA countries could be pooled for the 
primary outcome analysis - in which 37,195 products were transfused to 33,229 patients. 
Secondly, there was heterogeneity across the individual studies in reporting the diagnostic 
categories. As such, during our quantitative synthesis we tried to re-categorize some similar or 
over-lapping categories, although we could not do so in the case of two studies that used ICD-
10 disease categories. This may have risked introducing bias associated with this process of 
re-categorizing.  These limitations could be largely removed by a more comprehensive 
hemovigilance program for SSA.  
 
In summary, our study has merit because, it systematically attempts to estimate blood 
utilization in SSA. Blood products in SSA are used primarily for pediatric malaria, SCA, 
obstetric hemorrhage, and other causes of bleeding. Compared with high income countries, 
the transfusion index, transfusions per population and component transfusions for FFP and 
PLTs still remain low, while the use of WB is relatively high.    
 
Recommendations: Understanding blood utilization in SSA would be improved by 
standardized documentation of the diseases and diagnostic categories for which transfusion 
are given. Developing and implementing a standardized quality clinical transfusion use and 
management reporting system under a multi-nation bio-vigilance program could generate 
annual trends useful for documenting blood needs. In addition, improvement in diagnostic 
precision during routine clinical care would minimize the large numbers of ‘unknown 
anemias’ that were reported among many retrospective studies. Furthermore, comprehensive 
and larger prospective studies among a wide range of healthcare settings and levels would 
provide useful evidence on the possible trends of blood utilization in the region. 
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Table 1. Characteristics of studies on blood utilization in sub-Saharan 
Africa (n = 37) 
Variable Descriptive statistics 
Year of study (starting), Median (IQR*) 2009 (2005 – 2013) 
Study duration ( in months), Median (IQR) 12 (5.0 – 33.5) 
Study design, N (%) 
Retrospective 
Prospective 
Mixed 
 
20 (52.6) 
16 (42.1) 
1 (2.6) 
Study setting, N (%) 
Urban 
Rural 
Mixed 
Unknown 
 
27 (71.1) 
6 (15.8) 
3 (7.9) 
1 (2.6) 
Level of health facility, N (%) 
Tertiary 
Secondary 
Mixed 
 
28 (73.7) 
5 (13.2) 
4 (10.5) 
Blood products reported on, median (IQR) 2 (1-3) 
Number of patients transfused, median (IQR) 144 (100 – 670) 
Number of transfusions, median (IQR) 238 (141 – 887) 
*IQR = interquartile range 
 
 
 
 
Table 2. Blood utilization by the different wards in sub-Saharan Africa 
 Number of blood products used by each ward  
Author Pediatrics Medical Surgical Accident & 
Emergency 
Obstetrics & 
Gynecology 
Arewa et al (2009) 13  228 192 150 - 112 
Bugge et al (2013) 14 66 30 - - - 
Butler et al (2015) 7 700 1,349 901 517 1,404 
Drammeh et al (2017) 12 4,968 5,320 1,589 - 4,651 
Mbanya et al (2001) 15 17,128 4,999 - - 4,855 
Natukunda et al (2010) 16 724 453 21 158 318 
Traore et al (2011) 18 - - - - 168 
 Totals 23,814 
(47%) 
12,343 
(24%) 
2,661  
(5%) 
675  
(1%) 
11,508  
(23%) 
 
 
 
 
 
 
 
 
 
 
Table 3. Distribution of blood products use in sub-Saharan Africa 
 Type of blood product used  
Author RBCs  WB  FFP  PLTs  Totals 
Arewa et al (2009) 13  462 39 72 100 673 
Bugge et al (2013) 14  - 104 - - 104 
Butler et al (2015) 7 1,970 3,879 132 349 6,330 
Drammeh et al (2017) 12 283 13,416 251 234 14,184 
Mafirakureva et al (2015) 11 3,660 20 444 93 4,217 
Mbanya et al (2001) 15 - 26,982 - - 26,982 
Natukunda et al (2010) 16 1,151 1,621 - 5 2,777 
Pitman et al (2015) 8 78,660 - 9,751 2,978 91,389 
Tobi et al (2014) 17 50 362 12 - 424 
Traore et al (2011) 18 - 230 - - 230 
 Totals 86,236 
(58.5%) 
46,653 
(31.7%) 
10,662 
(7.2%) 
3,759 
(2.6%) 
147,310 
 
 
 
 
 
 
 
 
 
 
Appendices 
Appendix 1: The search strategy 
Embase (through Ovid); 
1. blood transfusion/ or blood component therapy/ or exchange blood transfusion/ 
2. transfusion.ti,ab,kw. 
3. exp "Africa south of the Sahara"/ or sub-Sahara.ti,ab. or sahara.ti,ab. or central africa.ti,ab. or Cameroon.ti,ab. or "Central African 
Republic".ti,ab. or Chad.ti,ab. or Congo.ti,ab. or "Democratic Republic of the Congo".ti,ab. or Equatorial Guinea.ti,ab. or Gabon.ti,ab. or 
Eastern africa.ti,ab. or Burundi.ti,ab. or Djibouti.ti,ab. or Eritrea.ti,ab. or Ethiopia.ti,ab. or Kenya.ti,ab. or Rwanda.ti,ab. or Somalia.ti,ab. 
or Sudan.ti,ab. or Tanzania.ti,ab. or Uganda.ti,ab. or Southern africa.ti,ab. or Angola.ti,ab. or Botswana.ti,ab. or Lesotho.ti,ab. or 
Malawi.ti,ab. or Mozambique.ti,ab. or Namibia.ti,ab. or South Africa.ti,ab. or Swaziland.ti,ab. or Zambia.ti,ab. or Zimbabwe.ti,ab. or 
Western africa.ti,ab. or Benin.ti,ab. or Burkina Faso.ti,ab. or Cape Verde.ti,ab. or "Cote d’Ivoire".ti,ab. or Gambia.ti,ab. or Ghana.ti,ab. or 
Guinea.ti,ab. or Guinea-Bissau.ti,ab. or Liberia.ti,ab. or Mali.ti,ab. or Mauritania.ti,ab. or Niger.ti,ab. or Nigeria.ti,ab. or Senegal.ti,ab. or 
Sierra Leone.ti,ab. or Togo.ti,ab. or Ivory Coast.ti,ab. or central africa.ad. or Cameroon.ad. or Central African Republic.ad. or Chad.ad. or 
Congo.ad. or Democratic Republic of the Congo.ad. or Equatorial Guinea.ad. or Gabon.ad. or Eastern africa.ad. or Burundi.ad. or 
Djibouti.ad. or Eritrea.ad. or Ethiopia.ad. or Kenya.ad. or Rwanda.ad. or Somalia.ad. or Sudan.ad. or Tanzania.ad. or Uganda.ad. or 
 
 
Southern africa.ad. or Angola.ad. or Botswana.ad. or Lesotho.ad. or Malawi.ad. or Mozambique.ad. or Namibia.ad. or South Africa.ad. or 
Swaziland.ad. or Zambia.ad. or Zimbabwe.ad. or west africa.ad. or Benin.ad. or Burkina Faso.ad. or Cape Verde.ad. or "Cote 
d’Ivoire".ad. or Gambia.ad. or Ghana.ad. or Guinea.ad. or Guinea-Bissau.ad. or Liberia.ad. or Mali.ad. or Mauritania.ad. or Niger.ad. or 
Nigeria.ad. or Senegal.ad. or Sierra Leone.ad. or Togo.ad. or Ivory Coast.ad. 
4. 1 or 2 
5. 3 and 4 
6. (elsevier or embase or canadian).cr. 
7. 5 and 6 
8. limit 7 to (conference abstract or conference paper or "conference review") 
9. 7 not 8 
10. case report/ 
11. 9 not 10 
12. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.) 
13. 11 not 12 
 
 
 
 
PubMed; 
#1. Search ((("Blood Component Transfusion"[Mesh]) OR "Exchange Transfusion, Whole Blood"[Mesh]) OR "Plasma Exchange"[Mesh]) OR 
"Blood Transfusion"[Mesh:NoExp] 
#2. Search transfusion[tiab] 
#3. Search #1 OR #2 
#4. Search ("africa south of the sahara"[MeSH Terms] OR "africa, central"[MeSH Terms] OR "cameroon"[MeSH Terms] OR "central african 
republic"[MeSH Terms] OR "chad"[MeSH Terms] OR "congo"[MeSH Terms] OR "democratic republic of the congo"[MeSH Terms] OR 
"equatorial guinea"[MeSH Terms] OR "gabon"[MeSH Terms] OR "africa, eastern"[MeSH Terms] OR "burundi"[MeSH Terms] OR 
"djibouti"[MeSH Terms] OR "eritrea"[MeSH Terms] OR "ethiopia"[MeSH Terms] OR "kenya"[MeSH Terms] OR "rwanda"[MeSH Terms] OR 
"somalia"[MeSH Terms] OR "sudan"[MeSH Terms] OR "tanzania"[MeSH Terms] OR "uganda"[MeSH Terms] OR "africa, southern"[MeSH 
Terms] OR "angola"[MeSH Terms] OR "botswana"[MeSH Terms] OR "lesotho"[MeSH Terms] OR "malawi"[MeSH Terms] OR 
"mozambique"[MeSH Terms] OR "namibia"[MeSH Terms] OR "south africa"[MeSH Terms] OR "swaziland"[MeSH Terms] OR 
"zambia"[MeSH Terms] OR "zimbabwe"[MeSH Terms] OR "africa, western"[MeSH Terms] OR "benin"[MeSH Terms] OR "burkina 
faso"[MeSH Terms] OR "cape verde"[MeSH Terms] OR "Cote d'Ivoire"[MeSH] OR "gambia"[MeSH Terms] OR "ghana"[MeSH Terms] OR 
"guinea"[MeSH Terms] OR "guinea-bissau"[MeSH Terms] OR "liberia"[MeSH Terms] OR "mali"[MeSH Terms] OR "mauritania"[MeSH 
 
 
Terms] OR "niger"[MeSH Terms] OR "nigeria"[MeSH Terms] OR "senegal"[MeSH Terms] OR "sierra leone"[MeSH Terms] OR "togo"[MeSH 
Terms] OR sub-Sahara[tiab] OR sahara[tiab] OR central africa[tiab] OR Cameroon[tiab] OR Central African Republic[tiab] OR Chad[tiab] OR 
Congo[tiab] OR "Democratic Republic of the Congo"[tiab] OR Equatorial Guinea[tiab] OR Gabon[tiab] OR Eastern africa[tiab] OR 
Burundi[tiab] OR Djibouti[tiab] OR Eritrea[tiab] OR Ethiopia[tiab] OR Kenya[tiab] OR Rwanda[tiab] OR Somalia[tiab] OR Sudan[tiab] OR 
Tanzania[tiab] OR Uganda[tiab] OR Southern africa[tiab] OR Angola[tiab] OR Botswana[tiab] OR Lesotho[tiab] OR Malawi[tiab] OR 
Mozambique[tiab] OR Namibia[tiab] OR South Africa[tiab] OR Swaziland[tiab] OR Zambia[tiab] OR Zimbabwe[tiab] OR Western africa[tiab] 
OR Benin[tiab] OR Burkina Faso[tiab] OR Cape Verde[tiab] OR "Cote d'Ivoire"[tiab] OR Gambia[tiab] OR Ghana[tiab] OR Guinea[tiab] OR 
Guinea-Bissau[tiab] OR Liberia[tiab] OR Mali[tiab] OR Mauritania[tiab] OR Niger[tiab] OR Nigeria[tiab] OR Senegal[tiab] OR Sierra 
Leone[tiab] OR Togo[tiab] OR Ivory Coast[tiab] OR central africa[Ad] OR Cameroon[Ad] OR Central African Republic[Ad] OR Chad[Ad] OR 
Congo[Ad] OR Democratic Republic of the Congo[Ad] OR Equatorial Guinea[Ad] OR Gabon[Ad] OR Eastern africa[Ad] OR Burundi[Ad] OR 
Djibouti[Ad] OR Eritrea[Ad] OR Ethiopia[Ad] OR Kenya[ad] OR Rwanda[Ad] OR Somalia[Ad] OR Sudan[Ad] OR Tanzania[Ad] OR 
Uganda[Ad] OR Southern africa[Ad] OR Angola[Ad] OR Botswana[Ad] OR Lesotho[Ad] OR Malawi[Ad] OR Mozambique[Ad] OR 
Namibia[Ad] OR South Africa[Ad] OR Swaziland[Ad] OR Zambia[ad] OR Zimbabwe[Ad] OR west africa[ad] OR Benin[ad] OR Burkina 
Faso[Ad] OR Cape Verde[Ad] OR "Cote d'Ivoire"[Ad] OR Gambia[Ad] OR Ghana[ad] OR Guinea[Ad] OR Guinea-Bissau[Ad] OR Liberia[ad] 
OR Mali[Ad] OR Mauritania[Ad] OR Niger[Ad] OR Nigeria[Ad] OR Senegal[Ad] OR Sierra Leone[Ad] OR Togo[Ad] OR Ivory Coast[Ad]) 
#5. Search #3 AND #4 
 
 
AIM; 
1. transfusion AND (instance:"ghl") AND ( db:("AIM")) 
 
Appendix 2: The protocol_ Blood utilization in sub-Saharan Africa: a systematic review of current data 
Introduction 
The demand for blood transfusion in sub-Saharan Africa (SSA) from severe anemia conditions such as malarial anemia, obstetric hemorrhage, 
trauma, and sickle cell anemia far exceeds the current supply, with a shortfall of about 50%.1 It has been postulated that the human population 
growth in the region, coupled with other factors such as weak and unsustainable donor recruitment and retention systems are likely to further 
worsen the blood demand situation in the region.1,2 Although the main determinant of transfusion demand is the anemia burden which stands at 
60% in sub-Saharan Africa,3 to larger extent, blood utilization also is an important factor.   
Data on the current use of blood products for transfusion in sub-Saharan Africa is scarce, although estimates for the common indications for 
transfusion have been made. It is estimated that about 80% of all blood transfusions in SSA are given to three disease conditions, namely; 
Malaria, obstetric hemorrhage and accident related indications.1  
 
 
Evidence on the use of blood products in SSA is important both for informing best practices for appropriate use of blood, and for forecasting 
future demand for blood. Both of these two factors are very important to transfusion and the health care system in SSA. In the first place, because 
the demand-supply deficits of blood continue to plague the region and would require more prudent measures to ensure adequate blood supply. 
And secondly, the rapid changing dynamics in population growth and increase in life expectancy on one side4 versus uneven economic growth 
and varying disease epidemiology. Concerning the latter; there have been notable improvements in the epidemiology of some infectious diseases 
in the region such as the case of the promising impact of malaria elimination, 5,6 yet several other emerging health concerns such as Cancers and 
other Non-Communicable Diseases (NCDs) are on the increase.7,8 These driving forces among other factors will have unprecedented impact on 
the demand and use of blood products in SSA.    
There is therefore need to generate evidence on this subject that can aid future projections for transfusion needs and their implications on 
transfusion and health care services in the region. No prior review on this topic could be found. 
Aim: To review the current data on blood utilization in sub- Saharan Africa. 
Research question: What proportion of available blood products is used for transfusion for the different anemia related disease conditions in sub- 
Saharan African health facilities. 
“PICO” criteria: 
• P; population = sub- Saharan Africa health facilities 
 
 
• I; intervention or exposure = Transfusion  
• C; Comparison groups = Not applicable 
• O; Outcome = Blood utilization 
Our intervention of interest will include: Transfusion with any of the following blood products, at any dose, and for all indications; 
a) Packed Red blood cells ( RBCs) 
b) Whole blood (WB) 
c) Platelets (PLTs) 
d) Fresh frozen plasma (FFP) 
The outcome; The proportion of blood products used (during the specified time period; with enough information about numbers or percentages) 
for different diseases.  
Study population / setting will include: Health facilities (all levels) such as district hospitals, referral hospitals (both public and private) in sub-
Saharan Africa. sub-Saharan Africa includes all the 54 countries in Africa, excluding Algeria, Egypt, Libya, Morocco & Tunisia. 
Blood utilization: This will include all anemia related disease conditions specified, for which transfusions are given; whether broad or narrow, 
such as; Obstetrics and gynecology, pediatrics, trauma/accident/injuries, surgical, cancers or sickle cell anemia.  
 
 
Target evidence / study design: Cross sectional studies and cohorts. 
Methods: 
a) Inclusion criteria for studies: 
• Cross-sectional and cohort studies; both prospective and retrospective 
• Clinical trials can be included 
• Studies specifically designed to report on one or more categories of disease conditions using up one or more specified blood 
product(s). 
• Studies reporting on transfusion with any one or more of the following products, namely; Red blood cells ( RBCs), Whole blood 
(WB), Platelets, Plasma or Fresh frozen plasma. 
• Studies conducted in any one or more sub- Saharan African countries, 
• Studies published after 1st January 2000 
• Studies conducted at a specified level of H/facility; such as general Hospital, referral hospital etc. 
• Duration of the study must be specified 
• Conference abstracts reporting  on blood products use 
• Studies published in English or French. 
 
 
b) Exclusion criteria: 
• Studies whose observation period is < 1 month 
• Case reports and case series 
c) The search stategy: 
• Electronic searches 
• MEDLINE, through PubMED 
• EMBASE 
• Systematic “snow balling”; by looking at the reference lists of selected articles using Scopus citation database (backward 
searching) 
• In MEDILE; look up the articles that show up in “related articles”   
 
d) The search terms: 
P: (sub-Saharan Africa) OR Angola) OR Benin) OR Botswana) OR Burkina Faso) OR Burundi) OR Cameroon) OR Cape Verde) OR Central 
African Republic) OR Chad) OR Comoros) OR Congo) OR Democratic Republic of Congo) OR Djibouti) OR Equatorial Guinea) OR Eritrea) 
OR Ethiopia) OR Gabon) OR Gambia) OR Ghana) OR Guinea) OR Guinea-Bissau) OR Ivory Coast) OR Kenya) OR Lesotho) OR Liberia) OR 
Madagascar) OR Malawi) OR Mali) OR Mauritania) OR Mauritius) OR Mozambique) OR Namibia) OR Niger) OR Nigeria) OR Réunion) OR 
 
 
Rwanda) OR (Sao tome and principe) OR Senegal) OR Seychelles) OR Sierra Leone) OR Somalia) OR South Africa) OR South Sudan) OR 
Sudan) OR Swaziland) OR Tanzania) OR Togo) OR Uganda) OR Western Sahara) OR Zambia) OR Zimbabwe) 
                   AND 
I: (Transfusion) OR Blood transfusion) OR Erythrocyte transfusion) OR Blood component transfusion)  
                   AND 
C: N/A  
                  AND 
O : (Blood products) AND blood use) OR Blood utilization) 
e) Removal of duplicates 
• Duplicates in search results from MEDLINE and  EMBASE will be removed using endnote software 
f) Study selection screening: 
• Duplicate screening will be done; two researchers screening each paper 
• Screen titles and abstracts of all articles, then 
• Read the full text of the articles in the initial screen 
 
 
g) Data abstraction and management 
The following data will be extracted to an excel data sheet: 
• Author, year of publication,  
• Study setting, country,  
• Level of health facility, 
• Study design,  
• Study period,  
• Number of study participants, & their characteristics 
• Type and numbers of blood products reported,   
• Disease conditions treated 
• Outcome variable; the proportions of blood products utilized for the different disease categories. 
h) Statistical analysis and data synthesis strategy 
• A qualitative synthesis of the evidence will be done 
• Quantitative analysis will be done using Prism software (GraphPad). 
• Summary estimates will be grouped for the different disease conditions 
• We will estimate the number of blood products (and the 95% CI) 
 
 
• The relative ratios of; WB to packed RBCs, those of FFP to (WB + packed RBCs) and PLTs to (WB + packed RBCs) will be 
computed, as a measure of the current use of component therapy in SSA 
• We shall attempt to examine trends from the year 2000 to 2018, by spliting the data into into categories; 2000 – 2009 and 2009 – 
2018 
i) Management of bias 
• We will minimize selection bias; specifically selective outcome reporting, by contacting the authors of the different studies for 
details on the data and clarifications, 
• Regarding information bias, we will do double data abstraction. One researcher will abstract the data initially. A second researcher 
will then check these data for accuracy.  
j) Timelines for the review 
• Protocol development; May –June 2018 
• Electronic search ; June 2018 
• Screening and data abstraction : July 2018 
• Data analysis, synthesis and manuscript writing: Aug. 2018 
• Manuscript submission: Sept. 2018 
k) Limitations: 
 
 
The proportions reported in the papers could be based on a sizable percentage of blood products available for an entire nation; which does 
not tell us anything about the absolute amount of blood available.  For this reason therefore, we will focus on proportions, as the absolute 
numbers of blood products are beyond the scope of this current review. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
l) Analytical framework: 
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Appendix 3.1: A summary of 37 studies reporting blood utilization in sub-Saharan Africa (SSA) 
Author Country Year of 
study 
Study 
duration 
(Months) 
Study design Study 
setting 
Level of 
H/facility 
Number 
of H/- 
Facilities 
Blood 
components 
reported on 
Patients 
transfused 
Number  
of Blood 
products 
used 
Patient type 
transfused 
Akinola et al 
(2010) 37  
Nigeria 2007 3 Retrospective Urban Tertiary 1 not 
specified  
41 89 C/section births 
Akoko et al 
(2015) 43 
Tanzania 2013 8 Prospective Urban Tertiary 1 not 
specified 
105 153 Elective -Surgical 
Anorlu et al 
(2003) 32 
Nigeria 1995 36 Retrospective Urban Tertiary 1 not 
specified 
231 623 Obstetrics only 
Arewa et al 
(2009) 13 
Nigeria 2004 12 Prospective Urban Tertiary 1 4 682 772 General 
Bugge et al 
(2013) 14  
Malawi 2010 1 Prospective Rural Secondary 1 1 104 104 General 
 
 
Butler et al 
(2015) 7 
Uganda 2014 3 Prospective Urban Tertiary 1 4 3,662 6,330 General 
Chalya et al 
(2016) 44 
Tanzania 2013- 
2014 
12 Retrospective Urban Tertiary 1 not 
specified 
256 342 Elective major-
operations 
Drammeh et al 
(2017) 12 
Tanzania 2013 4 Prospective Mixed Mixed  Many 4 14,698 16,728 General 
Hume et al 
(2016) 45 
Uganda 2014 6 Prospective Urban Tertiary 1 1 50 323 Cancer patients 
Imarengiaye et al 
(2006) 38 
Nigeria 1998-
2002 
48 Retrospective Urban Tertiary 1 1 60 130 C/section births 
Lawson-
Ananissoh  et al 
(2015) 49 
Togo 2013 12 Retrospective Urban Tertiary 1 2 136 140 Hepato-
Gastroenterology  
Mafirakureva et 
al (2015) 11 
Zimbabwe 2012 12 Retrospective Urban Tertiary 4 5 1,793 4,249 General 
Magoha et al Kenya 1997 3 Prospective Urban Tertiary 1 1 63 67 Elective, Surgical 
 
 
(2001) 47 
Mbanya et al 
(2001) 15 
Cameroon 1994-
1998 
60 Retrospective Urban Tertiary 1 1 26,973 26,982 General 
Mosha et al 
(2009) 23 
Tanzania 2007 3 Prospective Rural Secondary 2 1 160 166 Pediatrics  
Mueller et al 
(2012) 24 
DRC 2009-
2010 
5 Prospective Rural Secondary 1 2 657 657 Pediatrics 
Murray et al 
(2011) 25 
South 
Africa 
2008 12 Retrospective Urban Tertiary 1 3 42 450 Pediatric oncology 
Natukunda et al 
(2010) 16 
Uganda 2008 12 Retrospective Rural Tertiary 1 3 1,674 2,777 General 
Obed et al 
(2010) 48 
Nigeria 1998-
2005 
96 Prospective Urban Tertiary 1 1 1,221 1,221 Obs & Gyn 
Ogunlesi et al, 
(2016) 26 
Nigeria 2013-
2014 
16 Prospective Urban Secondary 1 1 79 133 Pediatrics  
Ogunlesi et al Nigeria 2008 12 Retrospective Urban Tertiary 1 3 112 251 Newborns  
 
 
(2011) 40 
Orish et al 
(2016) 27 
Ghana 2010 36 Retrospective Urban Tertiary 1 not 
specified 
141 141 Pediatrics 
Lawani et al 
(2013) 33 
Nigeria 2012 12 Prospective not 
clear 
Tertiary 1 2 151 253 Obstetrics only 
Osei et al (2013) 
34 
Ghana 2011 3 Prospective Urban Tertiary 1 3 519 1001 Obs & Gyn 
Oseni et al 
(2008) 28 
Nigeria ? 12 Prospective Urban Tertiary 1 1 106 106 Pediatrics  
Ozumba et al 
(2009) 39 
Nigeria 2000 36 Retrospective Urban Tertiary 1 not 
specified 
117 212 C/section births 
Pam et al (2009) 
41 
Nigeria 2000-
2001 
9 Prospective Urban Tertiary 1 2 62 84 Newborns  
Pitman et al 
(2015) 8 
Namibia 2007 48 Mixed Mixed Mixed many 3 39,313 91,207 General 
Raban et al South 2009- 60 Retrospective Urban Tertiary 1 1 113 142 Newborns, 
 
 
(2015) 42 Africa 2013 Bleeding  
Salverda et al 
(2017) 29 
South 
Africa 
2009-
2014 
66 Retrospective Urban Tertiary 1 1 144 144 Pediatric trauma 
Sonnekus et al 
(2014) 46 
South 
Africa 
2012 3 Retrospective Urban Tertiary 1 1 148 174 General, 
Thrombocytopenic 
& bleeding 
Thomas et al 
(2017) 30 
Kenya 2013-
2016 
31 Retrospective Mixed Mixed 10 2 2,352 2,352 Pediatrics 
Tobi et al (2014) 
17 
Nigeria 2011-
2013 
24 Retrospective Urban Tertiary 1 3 191 424 ICU patients 
Traore et al 
(2011) 18 
Mali  2006 6 Prospective Rural Secondary 1 1 134 230 General 
Tsima et al 
(2016) 35 
Botswana 2014 8 Retrospective Rural nixed 4 4 71 117 Post-abortion only 
Ughasoro et al 
(2013) 31 
Nigeria 2011 12 Retrospective Urban Tertiary 1 4 95 238 Pediatrics  
 
 
Vandenberg et al 
(2016) 36  
South 
Africa 
2013 5 Retrospective Urban Tertiary 3 1 234 234 Obstetrics only 
Totals 96,690 159,746  
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 3.2: A summary of studies on general patient populations combined to evaluate blood utilization in SSA 
 Number of blood products used for each diagnostic category 
Author  Patient
s 
transfu
-sed 
Blood 
product
s used 
Pediatri
c 
malaria 
Other 
malari
a 
Obstetri
c 
hemorrh
-age & 
others  
Other 
bleedin
g  
Cancer
s 
Other 
NCDs & 
organ 
disorders
; e.g 
Diabetes 
HIV-
relate
d  
Other 
infec- 
tions 
SCA Traum
a (& 
burns) 
Surge-
ry 
(Non-
trauma
) 
Other 
medical 
condition
/ 
unknown 
anemia  
§ Arewa et al 
(2009) 13  
682 772 0* 0 * 0 * 242 0 * 89 0 * 0 * 0 * 0 * 158 283 
§ Bugge et al 
(2013) 14  
104 104 55 4 18 0 * 0 * 0 * 3 0 * 0 * 0 * 4 20 
§ Butler et al 
(2015) 7 
3,662 6,330 125 0 * 788 130 2,122 306 350 61 437 422 395 1,194 
Drammeh et 14,698 0 † 0 * 0 * 0 0 0 0 0 0 0 0 0 0 
 
 
al (2017) 12 
Mafirakureva 
et al (2015) 11 
1,793 0† 0 * 0 * 0 † 0 * 0 † 0 † 0 * 0 † 0 * 0 † 0 * 0 † 
§ Mbanya et 
al (2001) 15 
26,973 26,982 6,628 0 * 4,855 4,999 0 * 0 * 0 * 2,432 6,08
0 
0 * 0 * 1,987 
§ Natukunda 
et al (2010) 16 
1,674 2,777 556 362 261 562 217 118 0 * 533 11 63 55 39 
Pitman et al 
(2015) 8 
39,313 0 † 0 * 0 * 0 † 0 † 0 * 0 † 0 † 0 † 0 * 0 * 0 * 0 † 
Tobi et al 
(2014) 17 
191 0 ‡ 0 * 0 * 0 * 0 * 0 * 0 * 0 * 0 * 0 * 0 * 0 * 0 * 
§ Traore et al 
(2011) 18  
134 230 0 * 0 * 123 0 * 0 * 0 * 0 * 0 * 0 * 0 * 0 * 107 
 Totals 89,224 37,195 7,365 366 6,045 5933 2,339 513 353 3,026 6,52
8 
485 612 3,630 
 
 
*value not reported in the original study, †value not included in this analysis, ‡products had no diagnosis category reported on, not included in the 
primary outcome analysis, §the six studies used to determine the primary outcome. 
 
 
Appendix 3.3: A summary of blood utilization among pediatric only studies 
  Number of blood products used for each diagnostic category 
Author Overall No. 
of products  
used 
Malaria SCA Sepsis, 
Pneumonia & 
other infections 
Cancers Malnutrition Other conditions 
(Organ disorder, 
HIV, trauma) 
Mosha et al (2009) 23 166 157 - 1 - 1 1 
Mueller et al (2012) 24 657 565 - 115 - 31 - 
Murray et al (2011) 25 450 0 - - 450 - - 
Ogunlesi et al (2016) 26 133 75 19 - - - - 
Orish et al (2016) 27 141 83 - - - - 58 
 
 
Oseni et al (2008) 28 106 94 - 10 - - 4 
Salverda et al (2017) 29 144 - 
 
- - - 144 
Thomas et al (2017) 30 2,352 1,811 329 - - 188 118 
Ughasoro et al (2013) 31 238 25 28 36 75 13 37 
 Totals 4,387 2,810 376 162 525 233 362 
 
Appendix 3.4: A summary of blood utilization among obstetrics and gynecology only studies 
 Number of blood products used for each diagnostic category 
Author Blood 
products 
used 
APH PPH & other 
post-delivery 
complications, 
e.g sepsis 
Cesarean 
sections 
Cancers Abortions Ectopic preg. 
& ruptured 
uterus 
Others 
(causes of 
anemias) 
Anorlu et al (2003) 32 623 - 63 350 - - 104 106 
Lawani et al (2013) 33 253 29 224 - - - - - 
Osei et al (2013) 34 1001 158 237 39 168 108 128 148 
 
 
Tsima et al (2016) 35 117 - - - - 117 - - 
Vandenberg et al (2016) 36  234 - - 96 - - - 138 
  Totals 2,228 187 524 485 168 225 232 392 
 
 
 
Appendix 3.5: A summary of blood utilization among cesarean sections only studies 
 Number of blood products used for each diagnostic category 
Author Blood 
products used 
Placenta 
Previa 
Obstructed 
Labor 
Malpresenation PET & Fetal 
conditions 
Previous 
C/Section 
Others 
Akinola et al (2010) 37 * 89 -  -  -  -  -  -  
Imarengiaye et al (2006) 38 130 19 9 4 14 7 7 
Ozumba et al (2009) 39 212 28 35 12 9 24 9 
 Totals 431 47 44 16 23 31 16 
 *This study only reported cesarean sections as being emergence (70/89) or elective (19/89) 
 
 
Appendix 3.6: A summary of blood utilization among newborn only studies 
 Blood product used  Diagnostic category  
Author RBCs (#) WB (#) FFP (#) No. of blood 
products used 
Neonatal 
Jaundice 
Bleeding 
disorders & risk 
of bleeding 
Severe 
anemia 
Prophylaxis for 
planned surgery 
& others 
Ogunlesi et al (2011) 40  115 130 6 251 62 5 42 2 
Pam et al (2009) 41 30 54 0 84 48 3 32 1 
Raban et al (2015) 42 0 0 142 142 - 100 - 36 
 Total 145 184 148 477 110 108 74 39 
 
 
 
 
 
 
 
 
Appendix 3.7: Blood utilization in pediatrics, obstetrics and gynecology (OB/GY), cesarean section births and newborns 
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ns
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C/sections
22%
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10%
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Appendix 3.8:  A summary of studies on the utilization of platelets or autologous whole blood 
 Blood products used for each diagnostic category 
Blood 
product 
Author Total # 
products 
Patient type Leukemia Lymphomas, 
other cancers 
Marrow 
failure 
Surgery Obstetrics Gynecology 
Platelets Hume et al (2016) 45   323 Oncology 36 10 3 - - - 
Sonnekus et al (2014) 
46 * 
174 General, bleeding - - 69 13 - - 
Autologous 
blood 
Magoha et al (2001) 47  67 Elective, surgical - - 
 
67 - - 
Obed et al (2010) 48  1,221 Obstetrics & 
Gynecology 
- - - - 625 596 
*In this study, 84/174 records had missing diagnosis 
 
 
 
 
Fig. 1. Study-selection flow chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2143 potential studies; 
searched in Pubmed, Embase 
and African Index Medicus 
1 additional paper retrieved from reference 
list using Scopus citation database 
2033 records excluded at initial screening. 
Common reasons: studies were on donors, TTIs, 
severe anemia but no report on transfusion, studies 
on guinea pigs retrieved because of the country 
name, “Guinea” and pre-clinical animal studies,  
110 studies retrieved for 
detailed evaluation 
37 eligible studies   
74 studies excluded for the following reasons: 
• 32 studies with “no data on the primary 
outcome”; such as no details on the different 
disease conditions transfused, other transfusion 
outcomes e.g survival or death, reports on blood 
management or Hb thresholds, and audits of 
blood units and requests in hospital blood banks  
• 22 studies did not meet the inclusion criteria; 
studies on transfusion practice (bed-side & lab.), 
TTIs, transfusion reactions and blood donation 
• 10 reviews (no original data) 
• 5 letters to the editor 
• 3 studies on a different population (not sub-
Saharan Africa) 
• 1 duplicated study 
• 1 trial protocol 
 
 
Fig. 2. The geographical location and relative sample size of the 37 studies included 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Blood utilization by diagnostic categories in sub-Saharan Africa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
